Tofacitinib
| Evidence Level: N/A | Predicted Indications: 0 |
Table of Contents
- Tofacitinib
Tofacitinib: Known uses and market status in Australia
Summary
The TxGNN deep-learning model produced candidates for Tofacitinib, but every candidate that can be traced to a source is already a known use. There is therefore currently no new predicted indication for this drug. The one known use is listed below with its source.
Quick overview
| Item | Content |
|---|---|
| New predicted indications | None (all traceable model candidates are known uses) |
| Known uses among model candidates | 1 |
| Evidence level | Not applicable |
| Australia Market Status | Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data |
| Number of PBS Items | 1 (valid: 1) |
Known uses among the model’s candidates
Approved (supported by a licence or label)
| Indication | Source |
|---|---|
| rheumatoid arthritis | licence in another country |
Related to an approved indication (same disease category)
| Indication | Approved category |
|---|---|
| none | none |
Relations recorded in the knowledge graph (no approval found)
| Indication |
|---|
| none |
Australia Market Information
| Licence | Product | Dosage form | Status |
|---|---|---|---|
| 10511F | Xeljanz | Tablet 5 mg | Valid |
Safety Considerations
- Drug Interactions: The interaction screen returned 100 interactions in total. Major-level interactions listed among the first 20 entries are mostly with corticosteroids: hydrocortisone, triamcinolone (including ophthalmic), dexamethasone, betamethasone, budesonide, prednisone and prednisolone. Clarithromycin is also rated Major. Moderate interactions include aprepitant, morphine (including liposomal), opium, aspirin, omeprazole, esomeprazole, lansoprazole and miconazole. Zinc sulfate and zinc acetate are Minor.
- Malignancy signals: The literature includes reports of malignancy (CML, sebaceous carcinoma) in people exposed to tofacitinib or other immunosuppressants. Causality is not established, but this is relevant to any oncology-related repurposing.
- Immune deficiency: For the T-cell dysfunction syndrome (rank 9), tofacitinib’s immunosuppression could worsen the underlying immune deficiency.
For warnings and contraindications, please refer to the TGA-approved Product Information (PI).
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.